Hence, mutations to non-classic HR genes warrant continued exploration as a predictor of drug responses, particularly as PARP inhibitors advance in the treatment of other cancers, often in combination with chemotherapy or radiation [133,134,135,136,137,138,139,140,141,142]. This evidence concerns the gene PARP1 and cancer.